169 related articles for article (PubMed ID: 34474436)
1. The changing landscape for patients with relapsed/refractory acute myeloid leukaemia.
Isidori A; Ferrara F
Curr Opin Oncol; 2021 Nov; 33(6):635-641. PubMed ID: 34474436
[TBL] [Abstract][Full Text] [Related]
2. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
3. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
5. How I treat relapsed or refractory AML.
DeWolf S; Tallman MS
Blood; 2020 Aug; 136(9):1023-1032. PubMed ID: 32518943
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
7. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
8. Progress in the problem of relapsed or refractory acute myeloid leukemia.
Mims AS; Blum W
Curr Opin Hematol; 2019 Mar; 26(2):88-95. PubMed ID: 30640734
[TBL] [Abstract][Full Text] [Related]
9. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
10. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
11. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Bohl SR; Bullinger L; Rücker FG
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
[TBL] [Abstract][Full Text] [Related]
12. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
[TBL] [Abstract][Full Text] [Related]
13. Treatment for relapsed acute myeloid leukemia: what is new?
Ofran Y; Rowe JM
Curr Opin Hematol; 2012 Mar; 19(2):89-94. PubMed ID: 22227525
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
15. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.
Montesinos P; Bergua J; Infante J; Esteve J; Guimaraes JE; Sierra J; Sanz MÁ
Ann Hematol; 2019 Nov; 98(11):2467-2483. PubMed ID: 31667544
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
17. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
Lee E; Koh Y; Hong J; Eom HS; Yoon SS
J Korean Med Sci; 2021 Apr; 36(13):e85. PubMed ID: 33821592
[TBL] [Abstract][Full Text] [Related]
18. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
19. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
[TBL] [Abstract][Full Text] [Related]
20. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]